Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
about
EMAST is a Form of Microsatellite Instability That is Initiated by Inflammation and Modulates Colorectal Cancer ProgressionCombined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Beyond RAS and BRAF: a target rich disease that is ripe for pickingThe promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveBiomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and othersRole of Deficient Mismatch Repair in the Personalized Management of Colorectal CancerPD-1 Blockade in Tumors with Mismatch-Repair DeficiencyColorectal Carcinoma: A General Overview and Future Perspectives in Colorectal CancerClinical significance of mismatch repair gene expression in sporadic colorectal cancer.Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stagesPromoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients.BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers.A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatmentPrediction of biological behavior and prognosis of colorectal cancer patients by tumor MSI/MMR in the Chinese population.Twist1-induced epithelial-mesenchymal transition according to microsatellite instability status in colon cancer cellsClinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.Mismatch Repair Deficiency and Response to Immune Checkpoint BlockadeMolecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology.Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?Immune checkpoints and immunotherapy for colorectal cancer.Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications.Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.Recent progress in Lynch syndrome and other familial colorectal cancer syndromes.Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease.
P2860
Q26995653-AAA13320-E017-4D46-A8D6-D97CB8E42206Q27853216-6A8ED8BC-A1DC-46D3-808E-5AFB3011A23AQ28066095-BF6A5EC9-4B90-44F1-8ADB-FB210C43EE14Q28069924-28F4C255-D48B-403C-BD60-09F28942421EQ28070038-0179F39F-C9FA-4DC7-85F4-82B5F5A2A404Q28072468-358584E8-5D90-4FFD-B2EF-E7F1073901BEQ28080176-1F4DF11F-DD7C-4007-9150-86A912F9D0FFQ28262647-4BD17226-F06D-41F4-9A1D-C8D367E939D4Q30238915-2FDB91E8-DE51-4583-B985-F27881A5A773Q34292357-0D2A511A-8020-4B26-96BB-CF2077F9DE95Q35579056-0B5CC330-A49B-45A7-A36E-4A768A4C3D46Q35925613-84E240B7-528E-4CC6-8609-9A676BB5B97AQ36086837-99D718AE-5D73-419D-A4E1-E0C4BC71D36DQ36472959-3AC10E74-26BE-4595-A532-DAE208AFBF65Q37061363-8D9A740A-25C9-4A81-B940-A7691F35351DQ37203399-538A3EB5-CB71-4924-8770-AAC72CCA69D8Q37496562-8A20EA16-A485-4E3B-ABA3-1688377FDCB5Q37636754-33E00E54-119E-4B83-AA24-3DCD4683A7C1Q37741987-2D6D1D18-7F81-49F4-8D6A-18C77A8AE343Q38654591-CC7BF0A1-A0C5-42FE-9A3E-358169DF494EQ38739256-88620065-CC81-4C54-89CC-EC236F755315Q38828624-E72D2523-4B81-45B7-B9FA-0F7869D4A53CQ38868401-1EA64655-FA1A-4819-B879-D7637EA56AD5Q38895750-6397EEAC-1E64-4D35-9DB6-ABE83BF06DDBQ38938329-78F8E03C-03C7-42EC-92F7-5CC1F1377C04Q39038413-7B42DB64-7DD5-4C54-8B73-6567432724E2Q39038545-96467D95-DAD5-402A-A32C-9DD82CBCD8A5Q39395473-E8C69093-F045-4268-9208-218E9A97D943Q39967039-D650F65E-F671-4F8A-9E21-F4A97C98AE97Q40195853-C779FE76-D83A-40DE-90B6-6C5685AD2762Q40383388-7EC3F7CB-184C-4314-A717-B0C289B5E3FAQ40402615-72B94CEE-2722-41C9-B489-1C1346F6AD5DQ40428222-ABA96AB1-6081-4792-ADB2-2DA11346C1A6Q41093124-13320274-45FF-42A2-A9A6-AAF55F7C3988Q41352188-638CD1C7-EC00-4ECC-B620-1CA30719DA05Q42721528-A3EFE069-4664-4A86-AE0D-1AFEF36A4C24Q44995693-CE7F932A-A1D9-44D0-8B00-7AA9451A5356Q47634752-A288B413-DCCC-48D2-8096-F593F5202A7DQ53081522-5171DDB4-1DEE-4AA7-9BCC-A7C8E0EA0080Q54581789-A167F381-E7F7-4DCA-850E-93CD116461CF
P2860
Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Multicenter retrospective anal ...... satellite instability (MSI-H).
@ast
Multicenter retrospective anal ...... satellite instability (MSI-H).
@en
type
label
Multicenter retrospective anal ...... satellite instability (MSI-H).
@ast
Multicenter retrospective anal ...... satellite instability (MSI-H).
@en
prefLabel
Multicenter retrospective anal ...... satellite instability (MSI-H).
@ast
Multicenter retrospective anal ...... satellite instability (MSI-H).
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Multicenter retrospective anal ...... osatellite instability (MSI-H)
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDU100
P577
2014-02-27T00:00:00Z